SOURCE: Cerora

Cerora Presents Study Results on Their "Near the Field" Concussion Technology at the American Academy of Neurology Meeting April 30th

Presentations Include Clinical Results in Concussion as Well as in Alzheimer's Disease

Cerora, Inc., a StartUp Health / GE Healthcare Entrepreneurship program and Ben Franklin Technology Partners of Northeastern Pennsylvania company, is pleased to announce that 3 scientific presentations will be made at the American Academy of Neurology Annual meeting on April 30 in Philadelphia. These clinical findings result from the company's research collaborations with Lehigh University Sports Medicine and Tahoe Institute for Rural Health Research in concussion and earlier efforts with Palm Drive Hospital in Alzheimer's disease.

 

The three AAN presenters reporting results with Cerora's proprietary technology are:

 

1. Allan L. Bernstein, MD (AAN Neurologist member) who will present scientific abstract number 2039 entitled "A portable non-invasive biosensor based approach to actively assess cognitive function in Alzheimer's disease (AD) and beyond" as poster presentation P4.197 (scheduled to present during Poster Session IV on Wednesday, 4/30/2014 from 7:30 a.m. to 11:00 am).

 

2. Stephen J. Martino, MD (AAN Neurologist member) who will present scientific abstract number 3332 entitled "A portable non-invasive biosensor based approach to actively assess cognitive function and mild traumatic brain injury" as poster presentation P5.332 (scheduled during Poster Session V on Wednesday, 4/30/2014 from 3:00 p.m. to 6:30 p.m.).

 

3. Adam J. Simon, PhD (AAN Research Scientist member) will present scientific abstract number 4078 entitled "A Portable Non-invasive Biosensor based Approach to Actively Assess Sports Concussion and mild Traumatic Brain Injury" as poster presentation P5.299 (scheduled during Poster Session V on Wednesday, 4/30/2014 from 3:00 p.m. to 6:30 p.m.).

 

"The AAN Annual meeting will be a very important opportunity for Cerora to present and discuss our clinical data with the world's leading neurologists," commented Dr. Simon, who is Cerora's co-founder and CEO. "We are very pleased that our work was accepted for presentation because it will be critical to work closely with neurologists as the company builds its 'neurodiagnostics as a service' offering. Objective data -- provided rapidly, near the field in the case of concussion -- would offer a considerable advantage over current assessments which are typically based solely on subjective clinical impressions."

 

Cerora's proprietary MindReader™ brainwave sensing technology is designed to empower professionals to gather truly objective data, which, along with neuropsychological performance data, self-reporting of symptoms, and additional biosensor-based measures, can lead to more accurate determinations.

 

About Cerora

Cerora is leading the way in the development and testing of software and hardware technologies required to provide critically important, objective, portable biomarker-based brain-function diagnostic information. Located in the high-tech nexus at Ben Franklin Technology Partners of Northeastern Pennsylvania's TechVentures in Lehigh University's Mountaintop Campus in Bethlehem, Pennsylvania, the Company has assembled a team of experienced medical scientists and management professionals under the leadership of CEO Adam J. Simon, PhD, a noted physicist and globally-recognized brain biomarker expert.

 

For additional information please visit www.cerora.com

 

Media Contact:
Josh Weinstein
610-577-5388
jwemc2@rcn.com

Investor Relations Contact:
Russell Miller
310-386-2058
rustymil20@gmail.com

 

 

SOURCE: Cerora, Inc.